Crossmark

Predictive thresholds of peak and trough anti-Xa levels for bleeding risk in rivaroxaban-treated nonvalvular atrial fibrillation

Published Online: 2025-08-13

Authors

Almouwannes, Mouhammad Rida

Al-Bitar, Ahmad https://orcid.org/0009-0009-3173-1942
Ali, Tahani
License Information

Text and Data Mining valid from 2025-08-13

Version of Record valid from 2025-08-13
More Information

Article History

Received: 7 May 2025

Accepted: 23 July 2025

First Online: 13 August 2025

Declarations

:

: Ethical approval was obtained from the Biomedical Research Ethics Committee (BMREC; Approval ID: MD-011024-049054-02) at Damascus University.Informed consent was obtained from all participants prior to their inclusion in the study.

: Not applicable.

: The authors declare no competing interests.

Document is current